Ofatumumab-based chemoimmunotherapy effective in CLLHealioAn ofatumumab-based chemoimmunotherapy regimen was well tolerated and similarly effective as a rituximab-based regimen in previously untreated patients with chronic lymphocytic leukemia, accordi…
|
Homegrown Data Mining Uncovers Drug Claims That Are Most Likely to Have …
Atlantic Information Services, Inc. As a result, he and his team — a data analyst and a coder — are focusing on 16 drugs, including Rituximab, Herceptin and Lupron. They set a range of billable units for each drug. Claims for billable units within that range are probably compliant … |
|
A roundup of FDA oncology news from September 2013
Oncology Nurse Advisor … agent is indicated for use in persons who have chronic lymphocytic leukemia (CLL) or who have indolent B-cell non-Hodgkin lymphoma that has progressed during or within 6 months of treatment with rituximab (Rituxan®) or a rituximab-containing regimen. |
|
Biogen covers all bases for personalised approach to MS
PharmaTimes Data is also being presented on Biogen’s investigational MS drugs, such as Plegridy (pegylated interferon beta-1a), the pegylated version of its older blockbuster Avonex and daclizumab, a once-monthly subcutaneous injection being developed with AbbVie. |
Proactive Investors Australia |
Cellmid Limited receives federal research and development tax refund
Proactive Investors UK Recent studies have demonstrated that the company’s lead anti-midkine (MK) antibodies slowing primary tumour growth, reducing the spread of cancer and slowing the formation of blood vessels in different tumour types, which is a fundamental step in … CELLMID LIMITED : R&D Tax refund received4-traders (press release) |
Market watch: Upcoming market catalysts in Q4 2013Nature.comSubsequently, data from the second stage of the trial comparing obinutuzumab head-to-head against rituximab, which were both in combination with chlorambucil, demonstrated a significant improv…
Proactive Investors UK |
Cellmid’s midkine antibodies show effectiveness against cancer
Proactive Investors UK “We have postulated for some time that MK antibodies would have anti-cancer activities, via multiple mechanisms of action, and it is pleasing to see this confirmed in our own studies with our proprietary MK antibodies.” Cellmid’s cancer antibody … |
Proactive Investors Australia |
Cellmid Limited receives federal research and development tax refund
Proactive Investors Australia Recent studies have demonstrated that the company’s lead anti-midkine (MK) antibodies slowing primary tumour growth, reducing the spread of cancer and slowing the formation of blood vessels in different tumour types, which is a fundamental step in … CELLMID LIMITED : R&D Tax refund received4-traders (press release) |
Rituximab prevented corticosteroid-requiring chronic GVHDHealioRituximab prophylaxis considerably reduced corticosteroid-requiring chronic graft-vs.-host disease in patients who underwent allogeneic peripheral blood stem cell transplantation, according…
Proactive Investors Chinese |
Cellmid’s midkine antibodies show effectiveness against cancer
Proactive Investors Chinese Cellmid Limited (ASX: CDY) has completed several studies that demonstrate its lead anti-midkine (MK) antibodies efficacy in reducing cancer tumour growth and spread. The antibodies also slowed the formation of new blood vessels (angiogenesis) in … |